Cardiac Dysfunction in Cirrhotic Patients
Mostafa, M., Morsy, K., Zaghloul, A., Ahmed, M. (2017). Cardiac Dysfunction in Cirrhotic Patients. EKB Journal Management System, 21(2), 209-217. doi: 10.21608/smj.2017.53283
Mostafa Mostafa; Khairy Morsy; Amr Mohamed Zaghloul; Mohamed Ahmed. "Cardiac Dysfunction in Cirrhotic Patients". EKB Journal Management System, 21, 2, 2017, 209-217. doi: 10.21608/smj.2017.53283
Mostafa, M., Morsy, K., Zaghloul, A., Ahmed, M. (2017). 'Cardiac Dysfunction in Cirrhotic Patients', EKB Journal Management System, 21(2), pp. 209-217. doi: 10.21608/smj.2017.53283
Mostafa, M., Morsy, K., Zaghloul, A., Ahmed, M. Cardiac Dysfunction in Cirrhotic Patients. EKB Journal Management System, 2017; 21(2): 209-217. doi: 10.21608/smj.2017.53283

Cardiac Dysfunction in Cirrhotic Patients

Sohag Medical Journal
Article 24, Volume 21, Issue 2, July 2017, Page 209-217  XML PDF (73.62 K)
Document Type: Original Article
DOI: 10.21608/smj.2017.53283
View on SCiNiTO View on SCiNiTO
Authors
Mostafa Mostafa1; Khairy Morsy1; Amr Mohamed Zaghloul2; Mohamed Ahmed3
1Departments of Tropical medicine and Gastroenterology,Sohag Faculty of Medicine, Sohag University
2Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.
3Department of Internal medicine2,Sohag Faculty of Medicine, Sohag University
Abstract
Introduction:In the last 20 years a number of evidences suggested that cirrhosis regardless of its etiology, is associated with major cardiovascular anomalies. Overall these alterations are known as cirrhotic cardiomyopathy and a wide range of cardiovascular abnormalities including hyperdynamic circulation, enlargement or hypertrophy of different cardiac chambers and electrophysiological changes such as QT prolongation.
Aim of the work:to study the pattern and the extent of cardiac affection in cirrhotic patients and its relation to the Child-Pugh classification and its relation to MELD score.
Patients and Methods: Our study was carried out on 45 patients with liver cirrhosis, the diagnosis was depending on clinical evidence of stigmata of chronic liver disease (e.g.jaundice, ascites, etc), Ultrasonographic features of liver cirrhosis (e.g coarse echo texture, shrunken liver, etc) and laboratory investigations. Our study included 15 healthy controls. All patients were subjected to the complete history taking and physical examination, laboratory investigations: Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), serum alkaline phosphatase, serum albumin, Prothrombin time and concentration, Total, direct bilirubin, hepatitis markers for HBV and HCV, blood sugar, Hb , serum Creatinine, serum Sodium and serum Potassium, echo Doppler study included chamber sizes, interventricular  septum diameter, ejection fraction and diastolic function. All patients were classified according to the child-pugh classification and were be scored according to MELD score.
Results:In our study, only 22% of cases had no diastolic dysfunction, compared to 67% of controls. Also, 13.3% of cases had grade 2 diastolic dysfunction, compared to zero among controls. The difference was statistically significant. Diastolic dysfunction was significantly higher among Child class B and C compared to A (p=0.020). Although MELD increases steadily with second grade diastolic dysfunction, the difference was non significant. Diastolic dysfunction was more common among patients with larger amont of ascites, with significant difference. HE was significantly associated with diastolic dysfunction.
Conclusion:Our study concluded that diastolic dysfunction is an important pathological complication associated with liver cirrhosis and is directly related to the severity of liver cirrhosis.
 

 
Keywords
Liver cirrhosis; cirrhotic cardiomyopathy; systolic and diastolic dysfunction
Supplementary Files
References

1.Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24(2):451-9.

2.Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. Journal of the American College of Cardiology. 2010;56(7):539-49.

3.Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009;3:294–304.

4.Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Centers for Disease Control and Prevention website www cdcgov/nchs/data/nvsr/nvsr61/nvsr61_04pdf 2014.

5.Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. Journal of hepatology. 2013;58(3):593-608.

6.Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. . Hepatology American   Association   for   the   Study   of   Liver   Diseases   website. 2014(www.aasld.  org/practiceguidelines/Documents/Bookmarked%  20Practice % 20Guidelines/Chronic_Hep_B_Update_2009%20 8_24_2009.pdf. ).

7.Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293-302 e4.

8.Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. Journal of hepatology. 2012;56(4):810-8.

9.Brodehl A, Hedde PN, Dieding M, Fatima A, Walhorn V, Gayda S, et al. Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants. The Journal of biological chemistry. 2012;287(19):16047-57.

10.Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57(2):268-78

11.Moller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Digestive diseases and sciences. 2015;60(11):3209-25.

12.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8(3):308-15.

13.Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. Journal of the American College of Cardiology. 2004;44(6):1164-71.

14.Pall A, Czifra A, Vitalis Z, Papp M, Paragh G, Szabo Z. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. Journal of gastrointestinal and liver diseases : JGLD. 2014;23(3):301-10.

15.Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. The American journal of gastroenterology. 2005;100(5):1110-6.

16.Mota VGa, B F, Markman. . Echocardiography in Chronic Liver Disease: Systematic Review. . Arq Bras Cardiol, . 2013;100(4)::376-85.

17.Torregrosa M, Aguade S, Dos L, e ta, l. . Cardiac alterations in cirrhosis: reversibility after liver transplantation. Journal of hepatology. 2005;42:68-74.

18.Karagiannakis DS. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. . Hepatol Int 2014;8(4): :588-94. .

19.Dahl EK. Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. . Scand J Gastroenterol 2014;49(3): :362-72. .

20.Serste T. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. . Journal of hepatology. 2011;55(4): :794-9. 

Statistics
Article View: 227
PDF Download: 215